Leukotriene E4 in urine in patients with asthma and COPD-The effect of smoking habit

Respiratory Medicine

Volumn 101, Issue 4, 2007, Pages 826-832

  Gaki, E ^a   Papatheodorou, G ^b   Ischaki, E ^a   Grammenou, V ^a   Papa, I ^a   Loukides, S ^c  

^a Veterans Hospital of Athens   (Greece)

^b 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Eosinophils; Leukotriene E4; Smoking

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CREATININE; EOSINOPHIL CATIONIC PROTEIN; LEUKOTRIENE E4; PEPTIDOLEUKOTRIENE;

ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SMOKING HABIT; SPIROMETRY; SPUTUM ANALYSIS; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ASTHMA; CREATININE; EOSINOPHILIA; HUMANS; LEUKOTRIENE E4; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SMOKING; SPUTUM;

EID: 33847326694     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.06.031     Document Type: Article

References (24)

1. Wennergren G. Inflammatory mediators in blood and urine. Paediatr Respir Rev 1 (2000) 259-265
2. Saareks V., Riutta A., Alanko J., Ylitalo P., Parviainen M., Mucha I., et al. Clinical pharmacology of eicosanoids nicotine induced changes in man. J Physiol Pharmacol 51 (2000) 631-642
3. Mitsunobu F., Mifune T., Hosaki Y., Ashida K., Tsugeno H., Okamoto M., et al. Enhanced production of leukotrienes by peripheral leukocytes and specific igE antibodies in patients with COPD. J Allergy Clin Immunol 107 (2001) 492-498
4. Piperno D., Pacheco Y., Hosni R., Moliere P., Gharib C., Lagarde M., et al. Increased plasma levels of atrial natriuretic factor, renin activity and leukotriene C4 in chronic obstructive pulmonary disease. Chest 104 (1993) 454-459
5. Dahlen S.E. Pharmacological characterization of leukotrienes receptors. Am J Respir Crit Care Med 161 (2000) S41-S45
6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, April 2001; Update of the Management Sections, GOLD website 〈http://www.goldcopd.com〉. Date updated: July 2005.
7. Global strategy for asthma management and prevention. National Institutes of Health. National Heart, Lung and Blood Institute. NIH Publication No. 02-3659, 2005 updated.
8. Zervas E., Loukides S., Papatheodorou G., Psathakis K., Tsintiris K., Panagou P., et al. Magnesium levels in plasma and in erythrocytes before and after histamine challenge. Eur Respir J 16 (2000) 621-625
9. American Thoracic Society. Guidelines for metacholine and exercise challenge testing. Am J Respir Crit Care Med 161 (2000) 309-329
10. Standardization of Spirometry 1994. Update, American Thoracic Society. Am J Respir Crit Care Med 152 (1995) 1107-1136
11. Pizzichini E., Pizzichini M.M., Leigh R., Djukanovic R., and Sterk P.J. Safety of sputum induction. Eur Respir J Suppl 37 (2002) 9s-18s
12. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986) 307-310
13. 4 excretion in steroid treated patients with severe asthma. Respir Med 97 (2000) 1225-1229
14. 4 levels in acute asthma: correlation with airflow limitation. Thorax 59 (2004) 100-104
15. 4 during clinical course of chronic obstructive pulmonary disease. Prostaglandins Leukot Essent Fatty Acids 56 (1997) 213-217
16. Lee E., Robertson T., Smith J., and Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 161 (2000) 1881-1886
17. Rubinstein I., Kumar B., and Schriever C. Long-term montelukast therapy in moderate to severe COPD-a preliminary observation. Respir Med 98 (2004) 134-138
18. Yuksel H., Ozbilgin K., Coskun S., and Tuglu I. Protective effect of leukotriene receptor antagonist Montelukast on smoking-induced lung injury in wistar rats. Acta Med Okayama 57 (2003) 13-19
19. Kostikas K., Papatheodorou G., Psathakis K., Panagou P., and Loukides S. Prostaglandin E2 in the expired breath condensate of patients with asthma. Eur Respir J 22 (2003) 743-747
20. Tomlinson J.E., McMahon A.D., Chaudhuri R., Thompson J.M., Wood S.F., and Thomson N.C. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 60 (2005) 282-287
21. Pavord I.D., Ward R., Woltmann G., Wardlaw A.J., Sheller J.R., and Dworski R. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med 160 (1999) 1905-1909
22. Fauler J.C., and Frolich J.C. Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest 27 (1997) 43-47
23. Montuschi P., Kharitonov S.A., Ciabattoni G., and Barnes P.J. Exhaled leukotrienes and prostaglandins in COPD. Thorax 58 (2003) 585-588
24. Kumlin M., Stensvad F., Larsson L., Dahlen B., and Dahlen S.E. Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans. Clin Exp Allergy 25 (1995) 467-479